Eric Adler
Eric Adler is an expert in Cardiology at UC San Diego Health System (United States). As of October 2026, ScienceLeadR ranks Eric Adler in the top 1% of experts worldwide for Myocarditis, Cardiomyopathies and Heart Failure. Eric Adler has authored 395 publications, the most recent in 2026, and is an investigator in 14 clinical trials, 2 of them ongoing. SLR score: 1,605 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Transplantation - Genetics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2007 - 2026
Number : 395
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Clinical Characteristics and Outcomes of Hypertrophic Cardiomyopathy Associated With Thin Filament Variants: Insights From the SHaRe Registry. PMID 42779549 — registries, genes, genetics, amino acids, heart, arrhythmias, cardiac, atrial fibrillation, cardiomyopathy, hypertrophic, odds ratio, diagnosis, transplants, cardiomyopathies | Circ Genom Precis Med | 2026 | 0 |
| A translational model of MASLD-associated HFpEF defines mitochondrial dysfunction and cardiac plasticity during disease progression and regression. PMID 42331139 — mortality, fibrosis, heart, non-alcoholic fatty liver disease, disease progression, mitochondria, heart failure, diastolic, microscopy, electron, liver, diet, microscopy, myocytes, cardiac | Metabolism | 2026 | 0 |
| A pilot qualitative study of patient understanding and perceptions of genetic counselors and cascade testing in the context of transthyretin cardiac amyloidosis. PMID 42324791 — research design, pilots, genetic testing, heart failure, perception, informed consent, genetic services, prealbumin, genetic counseling, amyloidosis, cardiomyopathies, implementation science, transthyretin amyloidosis, transthyretin cardiac amyloidosis | J Genet Couns | 2026 | 0 |
| AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial. PMID 42307907 — genes, heart diseases, safety, serum, troponin, cardiovascular diseases, biopsy, friedreich ataxia, drug-related side effects and adverse reactions, myocarditis, ataxia, therapeutics, non-randomized controlled trials as topic, cardiomyopathies | JAMA Cardiol | 2026 | 3 |
| A Novel Model to Predict Progression to Death After Withdrawal of Care in Potential Donation-After-Circulatory-Death Heart Donors. PMID 42276522 — heart failure, heart | J Card Fail | 2026 | 0 |
Clinical Studies 14
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| LDL C Optimization Using Inclisiran in Patients in Which Drug Drug Interactions Limit LDL Lowering NCT06865885 — injections, comorbidity, polypharmacy, cholesterol, ldl, pharmaceutical preparations, cholesterol, autoimmune diseases, primary prevention, therapeutics, hydroxymethylglutaryl-coa reductase inhibitors, injections, subcutaneous, metabolic syndrome, drug interactions | Phase 4 | Recruiting | 2025 |
| MYTHS MYocarditis THerapy With Steroids NCT05150704 — prednisolone, methylprednisolone acetate, safety, saline solution, methylprednisolone, heart failure, heart, adrenal cortex hormones, acetates, solutions, myocarditis, therapeutics, immunosuppression therapy, steroids, methylprednisolone hemisuccinate, pulse | Phase 3 | Recruiting | 2021 |
LeadR Networks
Main global connection map